

# Scancell Holdings PLC

07:40 03 Apr 2018

## Scancell signs manufacturing agreement for its Moditope anti-cancer platform

Scancell Holdings Plc (LON:SCLP) has signed an agreement with The PolyPeptide Group for the manufacture of its first Moditope anti-cancer platform, Modi-1-AMPLIVANT.

The AIM-listed firm said that the contract with the independent contract manufacturer of therapeutic peptides was signed at the end of March 2018.

**READ: Scancell to work with Dutch firm on first on first product for Moditope cancer immune-therapy platform**

The cancer specialist said its Moditope platform acts by stimulating the production of CD4+ T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system.

Scancell said it plans to commence a phase I/II clinical trial of Modi-1-AMPLIVANT in the first half of 2019 in patients with triple-negative breast cancer, ovarian cancer and sarcomas.

Cliff Holloway, CEO of Scancell, said: "Commencing GMP manufacture is an important step in the development of our first Moditope product and is key to moving this novel therapy into the clinic in the first half of 2019."

**Price:** 4.96

**Market Cap:** £23.08 m

### 1 Year Share Price Graph



December 2018 June 2019 December 2019

### Share Information

**Code:** SCLP

**Listing:** LSE

**52 week High Low**  
10 3

**Sector:** Pharma & Biotech

**Website:** [www.scancell.co.uk](http://www.scancell.co.uk)

### Company Synopsis:

*Cancer remains one of the world's most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body's own natural defence mechanism - the immune system. Scancell's mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.*

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).